CXCL14 and head and neck squamous cell carcinoma: Interestingly, the oral administration of gefitinib, an inhibitor of EGF receptor, significantly (P < 0.001) reduces tumor growth of xenografts of three HNSCC cell lines (HSC-2, HSC-3, and HSC-4) in female athymic nude mice accompanied by an increase in CXCL14/BRAK expression specifically in the tumor tissue (Figures 3(a), 3(b), 3(c), and 3(e)).